drugset
drugset / Trial / NCT05154201

Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.

NCT05154201 ↗

Phase 1/2 Completed 150 enrolled Orinove, Inc. Fosun Pharma · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

Dose escalation of ORIN1001 in patients with advanced solid tumors. Dose escalation of ORIN1001 in combination with standard of care in patients with esophageal carcinoma, metastatic breast cancer, hepatocellular carcinoma, metastatic prostate cancer, pancreatic cancer, ovarian cancer and non-small cell lung cancer. Dose expansion of ORIN1001 as a single agent or in combination with standard of care in patients with advanced solid tumors.

Timeline

Start
2020-07-01
Primary completion
2023-01-30
Completion
2025-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ORIN1001 Unknown 100 mg Oral
Subject ORIN1001 Unknown 200 mg Oral
Subject ORIN1001 Unknown 300 mg Oral
Subject ORIN1001 Unknown 400 mg Oral
Subject ORIN1001 Unknown 500 mg Oral
Subject ORIN1001 Unknown 650 mg Oral
Subject ORIN1001 Unknown 900 mg Oral
Subject ORIN1001 Unknown 1200 mg Oral
Subject ORIN1001 Unknown 1500 mg Oral

Indications

No indication recorded.